Therapy News and Research

RSS

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

Study suggests that existing HIV drug could be a potential therapy for Staph infections

A new study by NYU School of Medicine researchers suggests that an existing HIV drug called maraviroc could be a potential therapy for Staphylococcus aureus, a notorious and deadly pathogen linked to hundreds of thousands of hospitalizations each year.

15 Dec 2012

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

The U.S. Food and Drug Administration today approved raxibacumab injection to treat inhalational anthrax, a form of the infectious disease caused by breathing in the spores of the bacterium Bacillus anthracis. Raxibacumab also is approved to prevent inhalational anthrax when alternative therapies are not available or not appropriate.

14 Dec 2012

Paroxetine could treat vascular complications of diabetes

University of Texas Medical Branch at Galveston researchers have discovered that the commonly used antidepressant drug paroxetine could also become a therapy for the vascular complications of diabetes.

14 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Novartis announced today that the US Food and Drug Administration (FDA) has approved Signifor (pasireotide) injection for the treatment of adult patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative.

14 Dec 2012

Cognitive therapy may reduce anxiety in bipolar patients

Mindfulness-based cognitive therapy may help reduce symptoms of anxiety in patients with bipolar disorder, researchers report.

14 Dec 2012

Combination therapy reduces sleep apnea symptoms at altitude

Patients with obstructive sleep apnea can better control their symptoms when traveling to higher altitudes by combining autoadjusted continuous positive airway pressure with acetazolamide, research suggests.

14 Dec 2012

Concern over enoxaparin bleeding risk in patients with moderate renal impairment

The low molecular weight heparin enoxaparin is associated with an increased risk for major bleeding in patients who have moderate renal impairment, say US scientists in findings that have prompted calls for updates to dosing recommendations.

14 Dec 2012

Definitions, responsibilities are crucial to medication reconciliation

To implement effective medication reconciliation, a definition of what the term means, as well as identification of who is responsible for the process, is necessary, show the results of a focus group-based study.

14 Dec 2012

NCC to expand women's cancer programs in the developing world

The National Cancer Coalition (NCC) is expanding its efforts to fight women's cancers in the developing world.

14 Dec 2012

Researchers turn light into heat on the nanoscale to trigger biochemical reactions

Since Edison's first bulb, heat has been a mostly undesirable byproduct of light. Now researchers at Rice University are turning light into heat at the point of need, on the nanoscale, to trigger biochemical reactions remotely on demand.

14 Dec 2012

Prostate cancer patients experience minimal relief from side effects following proton radiotherapy

Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation treatment called intensity modulated radiotherapy (IMRT), Yale School of Medicine researchers report in the Journal of the National Cancer Institute.

14 Dec 2012

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Cancer scientists led by Dr. John Dick at the Princess Margaret Cancer Centre have found a way to follow single tumour cells and observe their growth over time. By using special immune-deficient mice to propagate human colorectal cancer, they found that genetic mutations, regarded by many as the chief suspect driving cancer growth, are only one piece of the puzzle. The team discovered that biological factors and cell behaviour - not only genes - drive tumour growth, contributing to therapy failure and relapse.

14 Dec 2012

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.

14 Dec 2012

SLU researchers to study physiological and biochemical functions in lupus

Two researchers at Saint Louis University's division of rheumatology in the department of internal medicine have been awarded a $1.8 million NIH grant to study the physiological and biochemical functions in lupus, an autoimmune disease, and develop possible new medications for its treatment.

14 Dec 2012

Therapy News and Research

Iclusig gets FDA approval for two rare blood and bone marrow diseases

Study suggests that existing HIV drug could be a potential therapy for Staph infections

GSK receives FDA approval for raxibacumab to treat inhalational anthrax

Paroxetine could treat vascular complications of diabetes

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

FDA approves Novartis Signifor injection for treatment of Cushing's disease

Cognitive therapy may reduce anxiety in bipolar patients

Combination therapy reduces sleep apnea symptoms at altitude

Concern over enoxaparin bleeding risk in patients with moderate renal impairment

Definitions, responsibilities are crucial to medication reconciliation

NCC to expand women's cancer programs in the developing world

Researchers turn light into heat on the nanoscale to trigger biochemical reactions

Prostate cancer patients experience minimal relief from side effects following proton radiotherapy

Biological factors, cell behaviour drive tumour growth contributing to therapy failure and relapse

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

SLU researchers to study physiological and biochemical functions in lupus

At-home exercise regimen sufficient to increase cancer patients' mobility and reduce fatigue

CBT most effective for children with post-traumatic stress disorder

Diuretic-based antihypertensive therapy touted for obese

Massage could ease distress of brain cancer

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News